Extensive work has shown the dependence of the observed outcomes for TKI-based treatment on many parameters, including number and type of mutations in EGFR, KRAS mutations, MET (the hepatocyte growth factor receptor) amplification, and others [53,54,55], suggesting a great need for individualized strategies in the treatment of lung cancer patients. The gene discussed is MET; the disease is lung carcinoma.